The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.
 
Elia Aguado
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Teresa Macarulla
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Bin Fan
Employment - Agios
Stock and Other Ownership Interests - Agios
Travel, Accommodations, Expenses - Agios
 
Parham Nejad
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Sung Choe
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Patents derived from my work at Agios
Travel, Accommodations, Expenses - Agios
 
Liewen Jiang
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Camelia Gliser
Employment - Agios; KSQ Therapeutics (I)
Stock and Other Ownership Interests - Agios; Agios (I); KSQ Therapeutics (I); KSQ Therapeutics (I); KSQ Therapeutics (I)
 
Shuchi Sumant Pandya
Employment - Agios
Stock and Other Ownership Interests - Agios
Research Funding - Agios
Travel, Accommodations, Expenses - Agios
 
Bin Wu
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios